Decoy Therapeutics CEO to Discuss Accelerated Antiviral Development at hVIVO Event
Event summary
- Decoy Therapeutics CEO Rick Pierce to speak at hVIVO Capital Markets Day in London on June 11, 2026.
- Event focuses on early clinical development and human challenge trials for faster drug development.
- Decoy's pan-coronavirus program targeting clinic entry in 2027.
- Company's IMP³ACT platform combines AI-assisted design and rapid synthesis for antiviral development.
The big picture
Decoy Therapeutics is positioning itself at the forefront of antiviral innovation by leveraging AI-driven design and strategic partnerships to accelerate drug development. The company's focus on pan-coronavirus solutions aligns with growing industry interest in broad-spectrum antivirals, particularly in the wake of recent global health crises. The event underscores the increasing importance of human challenge trials in validating novel therapeutics more efficiently.
What we're watching
- Development Speed
- How Decoy's use of human challenge trials will impact its timeline to clinic.
- Strategic Partnerships
- Whether Decoy's collaboration with hVIVO will enhance its development capabilities.
- Market Differentiation
- The pace at which Decoy can establish its D-MAVs as a new category of antivirals.
Related topics